The University of Helsinki is a research-oriented university which offers stimulating and international environment. The Faculty of Medicine of the University of Helsinki, together with Helsinki University Central Hospital, The Helsinki Institute of Life Science, and the Institute for Molecular Medicine Finland forms the Academic Medical Center Helsinki. This medical campus ranks among the 10 best medical centers at European level and the 50 best centers in the world. More info on the Faculty or Medicine and AMCH can be found here:

https://www.helsinki.fi/en/faculty-of-medicine
https://www.helsinki.fi/en/meilahti-campus

Faculty of Medicine, Barborič laboratory, invites applications for a position of

DOCTORAL STUDENT OR POSTDOCTORAL RESEARCHER

in the field of RNA Polymerase II Gene Transcription for a fixed-term.

THE APPLICATION PERIOD HAS BEEN EXTENDED UNTIL JUNE 4, 2020. IF YOU HAVE SUBMITTED YOUR APPLICATION FOR THIS POSITION BY 25.5.2020, YOUR APPLICATION IS ALREADY UNDER CONSIDERATION.

The mission of the lab is to unravel fundamental mechanisms that control the elongation phase of transcription by RNA polymerase II (Pol II) in normal and disease states. We are particularly interested in essential and biomedically important cyclin-dependent kinases (CDKs) that trigger release of Pol II from promoter-proximal pausing and facilitate productive Pol II elongation along genes. We aim to exploit the knowledge on basic principles of gene regulation to help devise novel treatments of many diseases that stem from misregulated gene transcription programs. More information about the lab, including the latest research and news, can be found here: https://www.helsinki.fi/en/researchgroups/center-for-gene-regulation.

We are looking for a creative thinker with strong analytical skills and a passion for science. We expect you to formulate your own hypotheses, propose experimental design to address them, and take advantage of the laboratory/research community’s intellectual and skill resources to advance the knowledge of the field. The competitive candidate should hold MSc or PhD degree in molecular biology, biochemistry, biotechnology or related fields. Expertise in biochemistry and molecular biology is a pre-requisite for the position. In addition, we appreciate fluency in the analysis of NGS data. Excellent publication record (postdoctoral applicants) as well as strong command in written and spoken English is required.

The successful candidate will receive training in a cutting-edge genetic method at the laboratory of our collaborator at University of California, San Francisco. Our current projects, which are funded by Academy of Finland, Sigrid Juselius Foundation, and the Rivkin Center for Ovarian Cancer Research, lurk at the intersection of transcription, disease, and RNA biology. We are addressing significance of transcripitional CDKs for cancer, uncovering novel modes of controlling Pol II pause release, and tackling how the COVID-19 coronavirus subverts gene regulation machinery of the host for its own benefit.

Salary of the selected candidate will be based on the University’s salary scheme for teaching and research personnel composed of task specific and personal performance components. A trial period of six months will be applied. The accepted student will be able to enroll in one of internationally and nationally networked doctoral programmes, such as Doctoral Programme in Biomedicine. More info on the programmes can be found here:
https://www.helsinki.fi/en/research/doctoral-education/doctoral-schools-....

Your application should include a motivation letter with a summary of your interests, your CV, and two letters of reference.

Please submit your application, together with the required attachments, through the University of Helsinki electronic recruitment system by clicking on the ‘Apply for the position’ button. Internal applicants (i.e., current employees of the University of Helsinki) submit their applications through the SAP HR portal.

The closing date for applications is June 4, 2020. The shortlisted candidates will be notified about the interview shortly afterwards.

For further information, please contact Matjaž Barborič, Ph.D.; matjaz.barboric(at)helsinki.fi.

Recent publications:

Frilander MJ, Barborič M (2020) The Interlocking Lives of LARP7: Fine-Tuning Transcription, RNA Modification, and Splicing through Multiple Non-coding RNAs. Molecular Cell 78(1): 5-8.
Bugai A et al. (2019) P-TEFb activation by RBM7 shapes a pro-survival transcriptional response to genotoxic stress. Molecular Cell 74(2): 254-267.
Quaresma AJ, Bugai A, Barborič M (2016) Cracking the control of RNA polymerase II elongation by 7SK snRNP and P-TEFb. Nucleic Acids Res. 44: 7527-7539.
Barborič M, Fujinaga K (2016) The two sides of Tat. Elife; doi: 10.7554/eLife.12686.
Ekumi KM, et al. (2015) Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex. Nucleic Acids Res. 43: 2575-2589.

Due date

04.06.2020 23:59 EEST